Interleukin (IL)-9, a pleiotropic cytokine produced by the Th2 subset of T lymphocytes has been proposed as product of a candidate gene responsible for asthma. Its wide range of biological functions on many cell types involved in the allergic immune response suggests a potentially important role in the complex pathogenesis of asthma. To investigate the contributions of IL-9 to airway inflammation and airway hyperresponsiveness in vivo, we created transgenic mice in which expression of the murine IL-9 cDNA was regulated by the rat Clara cell 10 protein promoter. Lung selective expression of IL-9 caused massive airway inflammation with eosinophils and lymphocytes as predominant infiltrating cell types. A striking finding was the presence of increased numbers of mast cells within the airway epithelium of IL-9–expressing mice. Other impressive pathologic changes in the airways were epithelial cell hypertrophy associated with accumulation of mucus-like material within nonciliated cells and increased subepithelial deposition of collagen. Physiologic evaluation of IL-9–expressing mice demonstrated normal baseline airway resistance and markedly increased airway hyperresponsiveness to inhaled methacholine. These findings strongly support an important role for IL-9 in the pathogenesis of asthma.
Skip Nav Destination
Article navigation
5 October 1998
Article|
October 05 1998
Expression of Interleukin 9 in the Lungs of Transgenic Mice Causes Airway Inflammation, Mast Cell Hyperplasia, and Bronchial Hyperresponsiveness
Ulla-Angela Temann,
Ulla-Angela Temann
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
Search for other works by this author on:
Gregory P. Geba,
Gregory P. Geba
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
Search for other works by this author on:
John A. Rankin,
John A. Rankin
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
Search for other works by this author on:
Richard A. Flavell
Richard A. Flavell
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
Search for other works by this author on:
Ulla-Angela Temann
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
Gregory P. Geba
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
John A. Rankin
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
Richard A. Flavell
From the *Section of Immunobiology and ‡Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut 06520; §Pulmonary and Critical Care Medicine, Veteran's Administration Connecticut Health Care System, West Haven, Connecticut 06516; and the ‖Howard Hughes Medical Institute, New Haven, Connecticut 06520
Address correspondence to Richard A. Flavell, Howard Hughes Medical Institute and Section of Immunobiology, Yale University School of Medicine, 310 Cedar St., New Haven, CT 06520. Phone: 203-737-2216; Fax: 203-785-7561; E-mail: [email protected]
Received:
February 24 1998
Revision Received:
July 09 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 188 (7): 1307–1320.
Article history
Received:
February 24 1998
Revision Received:
July 09 1998
Citation
Ulla-Angela Temann, Gregory P. Geba, John A. Rankin, Richard A. Flavell; Expression of Interleukin 9 in the Lungs of Transgenic Mice Causes Airway Inflammation, Mast Cell Hyperplasia, and Bronchial Hyperresponsiveness . J Exp Med 5 October 1998; 188 (7): 1307–1320. doi: https://doi.org/10.1084/jem.188.7.1307
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement